{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:24:07Z","timestamp":1788355447398,"version":"build-2803163510"},"reference-count":91,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathologie Biologie"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.patbio.2015.03.001","type":"journal-article","created":{"date-parts":[[2015,4,5]],"date-time":"2015-04-05T12:44:02Z","timestamp":1428237842000},"page":"136-143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Pathophysiology and treatment of typical and atypical hemolytic uremic syndrome"],"prefix":"10.1016","volume":"63","author":[{"given":"C.","family":"Picard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Burtey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bornet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Curti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Montana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Vanelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.patbio.2015.03.001_bib0460","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.arcped.2011.04.001","article-title":"Syndrome h\u00e9molytique et ur\u00e9mique post-diarrh\u00e9ique\u00a0: quand y penser\u00a0? Quel suivi\u00a0?","volume":"18","author":"Bertholet-Thomas","year":"2011","journal-title":"Arch Pediatr"},{"issue":"5","key":"10.1016\/j.patbio.2015.03.001_bib0465","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00431-009-1079-9","article-title":"Hemolytic-uremic syndrome in Switzerland: a nationwide surveillance 1997\u20132003","volume":"169","author":"Schifferli","year":"2010","journal-title":"Eur J Pediatr"},{"issue":"3","key":"10.1016\/j.patbio.2015.03.001_bib0470","first-page":"257","article-title":"Haemolytic-uraemic syndrome as a sequela of diarrhoeal disease","volume":"30","author":"Fisher Walker","year":"2012","journal-title":"J Health Popul Nutr"},{"key":"10.1016\/j.patbio.2015.03.001_bib0475","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMe1110896","article-title":"Deconstructing a lethal foodborne epidemic","volume":"365","author":"Blaser","year":"2011","journal-title":"N Engl J Med"},{"issue":"3 Pt 2","key":"10.1016\/j.patbio.2015.03.001_bib0480","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1016\/j.lpm.2011.11.013","article-title":"Management of hemolytic uremic syndrome","volume":"41","author":"Loirat","year":"2012","journal-title":"Presse Med"},{"key":"10.1016\/j.patbio.2015.03.001_bib0485","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1086\/508207","article-title":"What makes an enterohemorrhagic Escherichia coli?","volume":"43","author":"Orth","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"S4","key":"10.1016\/j.patbio.2015.03.001_bib0490","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0929-693X(01)80197-4","article-title":"Syndrome h\u00e9molytique et ur\u00e9mique\u00a0: aspects microbiologiques","volume":"8","author":"Mariani-Kurkdjian","year":"2001","journal-title":"Arch Pediatr"},{"issue":"12","key":"10.1016\/j.patbio.2015.03.001_bib0495","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1182\/blood-2011-06-363648","article-title":"Shiga toxin (Stx) 1B and Stx 2B induce von Willebrand factor secretion from human umbilical vein endothelial cells through different signaling pathways","volume":"118","author":"Liu","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.patbio.2015.03.001_bib0500","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1128\/IAI.64.8.3294-3300.1996","article-title":"Translocation of Shiga toxin across polarized intestinal cells in tissue culture","volume":"64","author":"Acheson","year":"1996","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.patbio.2015.03.001_bib0505","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/030098589102800109","article-title":"Reproduction of edema disease of swine with purified Shiga-like toxin II variant","volume":"28","author":"MacLeod","year":"1991","journal-title":"Vet Pathol"},{"issue":"4","key":"10.1016\/j.patbio.2015.03.001_bib0510","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1189\/jlb.0308157","article-title":"Interactions between Shiga toxins and human polymorphonuclear leukocytes","volume":"84","author":"Brigotti","year":"2008","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.patbio.2015.03.001_bib0515","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1100\/tsw.2007.172","article-title":"Role of polymorphonuclear leukocytes in the pathophysiology of typical hemolitic uremic syndrome","volume":"7","author":"Exeni","year":"2007","journal-title":"Sci World J"},{"issue":"11","key":"10.1016\/j.patbio.2015.03.001_bib0520","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1099\/jmm.0.47282-0","article-title":"Differential binding of Shiga toxin 2 to human and murine neutrophils","volume":"56","author":"Griener","year":"2007","journal-title":"J Med Microbiol"},{"issue":"11","key":"10.1016\/j.patbio.2015.03.001_bib0525","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1182\/blood.V95.11.3396","article-title":"Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome","volume":"95","author":"Te Loo","year":"2000","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.patbio.2015.03.001_bib0530","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00467-007-0512-4","article-title":"Interactions of Shiga-like toxin with human peripheral blood monocytes","volume":"22","author":"Geelen","year":"2007","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"10.1016\/j.patbio.2015.03.001_bib0535","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1182\/blood.V88.1.174.174","article-title":"Effects of verocytotoxin on nonadherent human monocytes: binding characteristics, protein synthesis, and induction of cytokine release","volume":"88","author":"Van Setten","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.patbio.2015.03.001_bib0540","first-page":"195","article-title":"Shiga toxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies","volume":"6","author":"Keir","year":"2012","journal-title":"Drug Des Dev Ther"},{"issue":"9","key":"10.1016\/j.patbio.2015.03.001_bib0545","doi-asserted-by":"crossref","first-page":"e6990","DOI":"10.1371\/journal.pone.0006990","article-title":"Shiga toxin and lipopolysaccharide induce platelet-leukocyte aggregates and tissue factor release, a thrombotic mechanism in hemolytic uremic syndrome","volume":"4","author":"St\u00e5hl","year":"2009","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.patbio.2015.03.001_bib0550","first-page":"83","article-title":"R\u00f4le de la s\u00e9lectine P (CD62P) dans les interactions des cellules endoth\u00e9liales et des plaquettes activ\u00e9es avec les leucocytes","volume":"1","author":"McGregor","year":"1995","journal-title":"Hematologie"},{"issue":"6","key":"10.1016\/j.patbio.2015.03.001_bib0555","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1055\/s-0030-1262883","article-title":"Complement in typical hemolitic uremic syndrome","volume":"36","author":"Orth","year":"2010","journal-title":"Semin Thromb Hemost"},{"issue":"20","key":"10.1016\/j.patbio.2015.03.001_bib0560","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1182\/blood-2010-09-309161","article-title":"Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli\u2013induced hemolytic uremic syndrome","volume":"117","author":"St\u00e5hl","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.patbio.2015.03.001_bib0565","doi-asserted-by":"crossref","first-page":"172","DOI":"10.4049\/jimmunol.1100491","article-title":"Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis","volume":"187","author":"Morigi","year":"2011","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.patbio.2015.03.001_bib0570","doi-asserted-by":"crossref","first-page":"6394","DOI":"10.4049\/jimmunol.0900151","article-title":"Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome","volume":"182","author":"Orth","year":"2009","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.patbio.2015.03.001_bib0575","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1172\/JCI57313","article-title":"The CXCR4\/CXCR7\/SDF-1 pathway contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome in human and mice","volume":"122","author":"Petruzziello-Pellegrini","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.patbio.2015.03.001_bib0580","doi-asserted-by":"crossref","first-page":"e673","DOI":"10.1542\/peds.2004-2236","article-title":"Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion","volume":"115","author":"Ake","year":"2005","journal-title":"Pediatrics"},{"issue":"10","key":"10.1016\/j.patbio.2015.03.001_bib0585","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/archpediatrics.2011.152","article-title":"Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome","volume":"165","author":"Hickey","year":"2011","journal-title":"Arch Pediatr Adolesc Med."},{"issue":"20","key":"10.1016\/j.patbio.2015.03.001_bib0590","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1182\/blood-2010-07-271445","article-title":"How I treat patients with thrombotic thrombocytopenic purpura: 2010","volume":"116","author":"Georges","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.patbio.2015.03.001_bib0595","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00467-010-1556-4","article-title":"aHUS caused by complement dysregulation: new therapies on the horizon","volume":"26","author":"Waters","year":"2011","journal-title":"Pediatr Nephrol"},{"issue":"11","key":"10.1016\/j.patbio.2015.03.001_bib0600","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s00467-011-1944-4","article-title":"Plasma therapy for atypical haemolytic uraemic syndrome associated with heterozygous factor H mutations","volume":"26","author":"Kim","year":"2011","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"10.1016\/j.patbio.2015.03.001_bib0605","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/cid\/cis299","article-title":"Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157","volume":"55","author":"Wong","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.patbio.2015.03.001_bib0610","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1128\/AAC.01783-09","article-title":"Different classes of antibiotics differentially influence Shiga toxin production","volume":"54","author":"McGannon","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.patbio.2015.03.001_bib0615","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/1471-2180-12-160","article-title":"Therapeutic concentrations of antibiotics inhibit Shiga toxin release from enterohemorrhagic E.\u00a0coli O104:H4 from the 2011 German outbreak","volume":"12","author":"Corogeanu","year":"2012","journal-title":"BMC Microbiol"},{"issue":"10","key":"10.1016\/j.patbio.2015.03.001_bib0620","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1001\/jama.2012.264","article-title":"Association between azithromycine therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4","volume":"307","author":"Nitschke","year":"2012","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.patbio.2015.03.001_bib0625","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal trombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.patbio.2015.03.001_bib0630","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1128\/IAI.00679-08","article-title":"Shiga toxin 2 targets the murine renal collecting duct epithelium","volume":"77","author":"Psotka","year":"2009","journal-title":"Infect Immun"},{"issue":"4","key":"10.1016\/j.patbio.2015.03.001_bib0635","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/infdis\/171.4.1042","article-title":"A phase I study of chemically synthesized verotoxin (Shiga-like toxin) Pk-trisaccharide receptors attached to chromosorb for preventing hemolytic-uremic syndrome","volume":"171","author":"Armstrong","year":"1995","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.patbio.2015.03.001_bib0640","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1001\/jama.290.10.1337","article-title":"Effect of an oral Shiga toxin binding agent on diarrhea associated hemolytic uremic syndrome in children: a randomized controlled trial","volume":"290","author":"Trachtman","year":"2003","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.patbio.2015.03.001_bib0645","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1086\/381130","article-title":"Prospects for preventing serious systemic toxemic complications of Shiga toxin\u00a0\u2013\u00a0producing Escherichia coli infections using Shiga toxin receptor analogues","volume":"189","author":"Karmali","year":"2004","journal-title":"J Infect Dis"},{"issue":"14","key":"10.1016\/j.patbio.2015.03.001_bib0650","doi-asserted-by":"crossref","first-page":"E2077","DOI":"10.1096\/fj.06-6572fje","article-title":"A multivalent peptide library approach identifies a novel Shiga toxin inhibitor that induces aberrant cellular transport of the toxin","volume":"20","author":"Nishikawa","year":"2006","journal-title":"FASEB J"},{"issue":"11","key":"10.1016\/j.patbio.2015.03.001_bib0655","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1007\/s00467-011-1913-y","article-title":"Rescue from lethal Shiga toxin 2-induced renal failure with a cell-permeable peptide","volume":"26","author":"Stearns-Kurosawa","year":"2011","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"10.1016\/j.patbio.2015.03.001_bib0660","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1086\/373996","article-title":"Assessment in mice of the therapeutic potential of tailored, multivalent Shiga toxin carbohydrate ligands","volume":"187","author":"Mulvey","year":"2003","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.patbio.2015.03.001_bib0665","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1128\/IAI.70.2.612-619.2002","article-title":"Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection","volume":"70","author":"Mukherjee","year":"2002","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.patbio.2015.03.001_bib0670","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1086\/323082","article-title":"Efficacy of postinfection treatment with anti-Shiga toxin (Stx) 2 humanized monoclonal antibody TMA-15 in mice lethally challenged with Stx-producing Escherichia coli","volume":"184","author":"Yamagami","year":"2001","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.patbio.2015.03.001_bib0675","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1128\/AAC.00343-09","article-title":"Safety and pharmacokinetics of Urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli","volume":"54","author":"Lopez","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.patbio.2015.03.001_bib0680","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1128\/AAC.49.5.1808-1812.2005","article-title":"Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c\u03b1Stx2 administered intravenously to healthy adult volunteers","volume":"49","author":"Dowling","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.patbio.2015.03.001_bib0685","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1128\/AAC.01661-08","article-title":"Safety and pharmacokinetic of chimeric anti-Shiga toxin 1 and anti-Shiga toxin 2 monoclonal antibodies in healthy volunteers","volume":"53","author":"Bitzan","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"26","key":"10.1016\/j.patbio.2015.03.001_bib0690","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMc1100859","article-title":"Eculizumab in severe Shiga toxin-associated HUS","volume":"364","author":"Lapeyraque","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.patbio.2015.03.001_bib0695","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1093\/ndt\/gfs394","article-title":"Best supportive care and therapeutic plasma exchange with or without Eculizumab in Shiga toxin-producing E.\u00a0coli O104:H4 induced haemolytic\u2013uraemic syndrome: an analysis of the German STEC-HUS registry","volume":"27","author":"Kielstein","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.patbio.2015.03.001_bib0700","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/ndt\/gft470","article-title":"Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab","volume":"29","author":"Delmas","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.patbio.2015.03.001_bib0705","doi-asserted-by":"crossref","first-page":"e928","DOI":"10.1542\/peds.2012-1466","article-title":"A novel strategy for hemolytic uremic syndrome: successful treatment with thrombomodulin \u03b1","volume":"131","author":"Honda","year":"2013","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.patbio.2015.03.001_bib0710","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1111\/ped.12165","article-title":"Efficacy of recombinant human soluble thrombomodulin for childhood hemolytic uremic syndrome","volume":"55","author":"Kawasaki y","year":"2013","journal-title":"Pediatr Int"},{"issue":"6066","key":"10.1016\/j.patbio.2015.03.001_bib0715","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1126\/science.1215930","article-title":"Manganese blocks intracellular trafficking of Shiga toxin and protects against Shiga toxicosis","volume":"335","author":"Mukhopadhyay","year":"2012","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.patbio.2015.03.001_bib0720","doi-asserted-by":"crossref","first-page":"e69823","DOI":"10.1371\/journal.pone.0069823","article-title":"Failure of manganese to protect from Shiga toxin","volume":"8","author":"Gaston","year":"2013","journal-title":"PLoS One"},{"issue":"15","key":"10.1016\/j.patbio.2015.03.001_bib0725","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1091\/mbc.E13-01-0057","article-title":"Shiga toxin-binding site for host cell receptor GPP130 reveals unexpected divergence in toxin-trafficking mechanisms","volume":"24","author":"Mukhopadhyay","year":"2013","journal-title":"Mol Biol Cell"},{"issue":"19","key":"10.1016\/j.patbio.2015.03.001_bib0730","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1091\/mbc.E14-05-1003","article-title":"Manganese induces oligomerization to promote down-regulation of the intracellular trafficking receptor used by Shiga toxin","volume":"25","author":"Tewari","year":"2014","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.patbio.2015.03.001_bib0735","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/asheducation.V2012.1.617.3798924","article-title":"Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated?","volume":"2012","author":"Nester","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.patbio.2015.03.001_bib0740","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1750-1172-6-60","article-title":"Atypical hemolytic uremic syndrome","volume":"6","author":"Loirat","year":"2011","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"10.1016\/j.patbio.2015.03.001_bib0745","doi-asserted-by":"crossref","first-page":"E1445","DOI":"10.1002\/humu.21256","article-title":"Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome","volume":"31","author":"Maga","year":"2010","journal-title":"Hum Mutat"},{"issue":"3","key":"10.1016\/j.patbio.2015.03.001_bib0750","doi-asserted-by":"crossref","first-page":"56","DOI":"10.5527\/wjn.v2.i3.56","article-title":"Update on hemolytic uremic syndrome: diagnostic and therapeutic recommendations","volume":"2","author":"Salvadori","year":"2013","journal-title":"World J Nephrol"},{"issue":"4","key":"10.1016\/j.patbio.2015.03.001_bib0755","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1182\/blood-2005-10-007252","article-title":"Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome","volume":"108","author":"Caprioli","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.patbio.2015.03.001_bib0760","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.molimm.2013.06.001","article-title":"Complement factor H related proteins (CFHRs)","volume":"56","author":"Skerka","year":"2013","journal-title":"Mol Immunol"},{"issue":"24","key":"10.1016\/j.patbio.2015.03.001_bib0765","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1093\/hmg\/ddg363","article-title":"Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease","volume":"12","author":"Caprioli","year":"2003","journal-title":"Hum Mol Genet"},{"issue":"5","key":"10.1016\/j.patbio.2015.03.001_bib0770","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/ng.2590","article-title":"Recessive mutations in DGKE cause atypical haemolytic-uremic syndrome","volume":"45","author":"Lemaire","year":"2013","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.patbio.2015.03.001_bib0775","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","article-title":"Drug-induced thrombotic microangiopathy: a systematic review of published reports","volume":"125","author":"Al-Nouri","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.patbio.2015.03.001_bib0780","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1055\/s-0030-1262890","article-title":"Plasmatherapy in atypical hemolytic and uremic syndrome","volume":"36","author":"Loirat","year":"2010","journal-title":"Semin Thromb Hemost"},{"issue":"8","key":"10.1016\/j.patbio.2015.03.001_bib0785","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00467-008-0803-4","article-title":"Efficacy of plasma therapy in atypical hemolytic uremic syndrome with complement factor H mutations","volume":"23","author":"Lapeyraque","year":"2008","journal-title":"Pediatr Nephrol"},{"issue":"11","key":"10.1016\/j.patbio.2015.03.001_bib0790","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1007\/s00467-008-0872-4","article-title":"Complement and the atypical hemolytic uremic syndrome in children","volume":"23","author":"Loirat","year":"2008","journal-title":"Pediatr Nephrol"},{"issue":"11","key":"10.1016\/j.patbio.2015.03.001_bib0795","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s00467-006-0237-9","article-title":"Secondary failure of plasma therapy in factor H deficiency","volume":"21","author":"Nathanson","year":"2006","journal-title":"Pediatr Nephrol"},{"issue":"10","key":"10.1016\/j.patbio.2015.03.001_bib0800","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1111\/j.1537-2995.2007.01405.x","article-title":"Complication of apheresis in children","volume":"47","author":"Michon","year":"2007","journal-title":"Transfusion"},{"issue":"1","key":"10.1016\/j.patbio.2015.03.001_bib0805","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2010050451","article-title":"The development of atypical hemolytic uremic syndrome depends on complement C5","volume":"22","author":"Goicoechea de Jorge","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"23","key":"10.1016\/j.patbio.2015.03.001_bib0810","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical haemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.patbio.2015.03.001_bib0815","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrneph.2012.214","article-title":"Use of Eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies","volume":"8","author":"Zuber","year":"2012","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"10.1016\/j.patbio.2015.03.001_bib0820","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/petr.12290","article-title":"Prophylactic eculizumab for kidney transplantation in a child with atypical hemolytic uremic syndrome due to complement factor H mutation","volume":"18","author":"Ranch","year":"2014","journal-title":"Pediatr Transplantation"},{"issue":"11","key":"10.1016\/j.patbio.2015.03.001_bib0825","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1097\/TP.0000000000000200","article-title":"Atypical hemolytic uremic syndrome recurrence after kidney transplantation","volume":"98","author":"Matar","year":"2014","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.patbio.2015.03.001_bib0830","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/ki.2013.447","article-title":"Anti-factor H autoantibody-associated hemolytic uremic syndrome: the earlier diagnosed and treated, the better","volume":"85","author":"Loirat","year":"2014","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.patbio.2015.03.001_bib0835","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/ki.2013.373","article-title":"Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children","volume":"85","author":"Sinha","year":"2014","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.patbio.2015.03.001_bib0840","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00467-014-2948-7","article-title":"Effect of plasma exchange and immunosuppressive medications on antibody titers and outcome in anti-complement factor H antibody-associated haemolytic uremic syndrome","volume":"30","author":"Khandelwal","year":"2015","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"10.1016\/j.patbio.2015.03.001_bib0845","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1053\/j.ajkd.2009.12.026","article-title":"Pulse cyclophosphamide therapy and clinical remission in atypical haemolytic uremic syndrome with anti-complement factor H autoantibodies","volume":"55","author":"Boyer","year":"2010","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.patbio.2015.03.001_bib0850","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-2141.2009.07916.x","article-title":"Clinical Practice Guidelines for the management of atypical Haemolytic Uraemic Syndrome in the United Kingdom","volume":"148","author":"Taylor","year":"2009","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.patbio.2015.03.001_bib0855","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1681\/ASN.2008080906","article-title":"Liver-kidney transplantation to cure atypical hemolytic uremic syndrome","volume":"20","author":"Saland","year":"2009","journal-title":"J Am Soc Neprol"},{"issue":"4","key":"10.1016\/j.patbio.2015.03.001_bib0860","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/s00467-003-1371-2","article-title":"Attempted treatment of factor H deficiency by liver transplantation","volume":"19","author":"Cheong","year":"2004","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"10.1016\/j.patbio.2015.03.001_bib0865","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/j.1600-6143.2005.00783.x","article-title":"Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor H gene mutation","volume":"5","author":"Remuzzi","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.patbio.2015.03.001_bib0870","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1111\/j.1600-6143.2011.03612.x","article-title":"Complement activation during liver transplantation\u00a0\u2013\u00a0special emphasis on patients with atypical hemolytic uremic syndrome","volume":"11","author":"Koskinen","year":"2011","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.patbio.2015.03.001_bib0875","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1053\/j.ajkd.2011.04.008","article-title":"Successful simultaneous liver-kidney transplant in an adult with atypical hemolytic uremic syndrome associated with a mutation in complement factor H","volume":"58","author":"Wilson","year":"2011","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.patbio.2015.03.001_bib0880","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2215\/CJN.02170508","article-title":"Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome","volume":"4","author":"Saland","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.patbio.2015.03.001_bib0885","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1600-6143.2007.02029.x","article-title":"Successful liver-kidney transplantation in two children with aHUS caused by a mutation in complement factor H","volume":"8","author":"Jalanko","year":"2008","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.patbio.2015.03.001_bib0890","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1111\/petr.12066","article-title":"Changing strategies for organ transplantation in atypical haemolytic uraemic syndrome: a tertiary case series","volume":"17","author":"Forbes","year":"2013","journal-title":"Pediatr Transplant"},{"issue":"6","key":"10.1016\/j.patbio.2015.03.001_bib0895","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.2215\/CJN.10181110","article-title":"Pre-emptive Eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome","volume":"6","author":"Nester","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.patbio.2015.03.001_bib0900","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s00467-011-1879-9","article-title":"Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome","volume":"26","author":"Weitz","year":"2011","journal-title":"Pediatr Nephrol"},{"issue":"9","key":"10.1016\/j.patbio.2015.03.001_bib0905","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1111\/j.1600-6143.2010.03228.x","article-title":"Successful isolated liver transplantation in a child with atypical hemolytic uremic syndrome and a mutation in complement factor H","volume":"10","author":"Haller","year":"2010","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.patbio.2015.03.001_bib0910","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1423-0410.2012.01610.x","article-title":"Purification and biochemical characterization of functional complement factor H from human plasma fractions","volume":"103","author":"Brandst\u00e4tter","year":"2012","journal-title":"Vox Sang"}],"container-title":["Pathologie Biologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0369811415000176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0369811415000176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T02:27:09Z","timestamp":1691548029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0369811415000176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":91,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0369811415000176"],"URL":"https:\/\/doi.org\/10.1016\/j.patbio.2015.03.001","relation":{},"ISSN":["0369-8114"],"issn-type":[{"value":"0369-8114","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathophysiology and treatment of typical and atypical hemolytic uremic syndrome","name":"articletitle","label":"Article Title"},{"value":"Pathologie Biologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.patbio.2015.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}